Uncategorized

Third time’s the charm for Replimune as melanoma drug earns FDA greenlight

Published

on

Replimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists and a 10-3 advisory committee vote in its favor.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version